Tempest Therapeutics Inc
NASDAQ:TPST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dreamfolks Services Ltd
NSE:DREAMFOLKS
|
IN |
|
Balrampur Chini Mills Ltd
NSE:BALRAMCHIN
|
IN |
|
Jiangsu Huaxin New Material Co Ltd
SZSE:300717
|
CN |
Tempest Therapeutics Inc
Operating Income
Tempest Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
Operating Income
-$36.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$16.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$3.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
Tempest Therapeutics Inc
Glance View
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.
See Also
What is Tempest Therapeutics Inc's Operating Income?
Operating Income
-36.4m
USD
Based on the financial report for Sep 30, 2025, Tempest Therapeutics Inc's Operating Income amounts to -36.4m USD.
What is Tempest Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
6%
Over the last year, the Operating Income growth was -2%. The average annual Operating Income growth rates for Tempest Therapeutics Inc have been -3% over the past three years , 3% over the past five years , and 6% over the past ten years .
